[{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Decibel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"Otoferlin","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Intracochlear Injection","sponsorNew":"Catalent Pharma Solutions \/ Decibel Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Decibel Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"Elasomeran","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"BrainStorm Cell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"BrainStorm Cell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesenchymal Stem Cell Secreting Neurotrophic Factors Cell","moa":"Neurotrophic factor","graph1":"Neurology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ AstraZeneca"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"TAK-919","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Moderna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Ad26.COV2.S","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"Catalent Pharma Solutions \/ GSK"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"ARCT-154","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Catalent Pharma Solutions \/ Arcturus Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Silexion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Collaboration","leadProduct":"SIL-204","moa":"KRAS G12D\/V","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Catalent Pharma Solutions \/ Silexion Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Silexion Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Sarepta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Rinvecalinase Alpha","moa":"KLK1","graph1":"Nephrology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalent Pharma Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Triphase Accelerator","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"Voclosporin","moa":"||Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Aurinia Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Pralsetinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Blueprint Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avapritinib","moa":"Platelet-derived growth factor receptor alpha | Stem cell growth factor receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Blueprint Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Blueprint Medicines"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Acorda Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"Dopamine D3 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Oral Inhalation Powder in Capsule","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"SIGA Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tecovirimat","moa":"Envelope phospholipase OPG057","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Phathom Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Vonoprazan Fumarate","moa":"||Potassium-transporting ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Phathom Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Incannex Healthcare"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Melt Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"BioSig Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Merimepodib","moa":"Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AustinPx","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Jupiter Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Agreement","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Catalent Pharma Solutions \/ Jupiter Neurosciences","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Jupiter Neurosciences"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ennaid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"ENU200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Ennaid Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Ennaid Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Curtana Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"CT-179","moa":"OLIG2","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Catalent Pharma Solutions \/ Curtana Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Curtana Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Siren Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Siren Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Siren Biotechnology"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Grunenthal","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Grunenthal","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Grunenthal"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"T-knife","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Midazolam","moa":"||GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"Beta-2 adrenergic receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"15","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Humanigen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"Lenzilumab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Humanigen","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Humanigen"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Edenbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Glycopyrronium Bromide","moa":"Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M3","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Edenbridge Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Harm Reduction Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Harm Reduction Therapeutics"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Acquisition","leadProduct":"Eryaspase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Catalent Pharma Solutions","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"9","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Bone Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Allogeneic Osteoblastic Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NTX-1175","moa":"Na channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Trizell","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Trizell","highestDevelopmentStatusID":"6","companyTruncated":"Catalent Pharma Solutions \/ Trizell"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Novan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berdazimer Sodium","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Catalent Pharma Solutions \/ Novan","highestDevelopmentStatusID":"5","companyTruncated":"Catalent Pharma Solutions \/ Novan"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Zumutor Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"ZM008","moa":"LLT1 antigen","graph1":"Oncology","graph2":"IND Enabling","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TSHA-118","moa":"Palmitoyl-protein thioesterase 1 (PPT1)","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Awakn Life Sciences Corp.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp.","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Awakn Life Sciences Corp."},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ethicann Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Cybin","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Cybin"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"ProtoKinetix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Anti-Aging Glycopeptide","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ AavantiBio"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"MigVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"MigVax-101","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ MigVax","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ MigVax"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"XB010","moa":"5T4 protein","graph1":"Oncology","graph2":"Discovery","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Catalent Pharma Solutions \/ Exelixis"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"JOS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ JOS Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ JOS Pharmaceuticals"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Spicona","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"VLP Based COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Spicona","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Spicona"}]
Find Clinical Drug Pipeline Developments & Deals by Catalent Pharma Solutions
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
